SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-212358
Filing Date
2023-08-14
Accepted
2023-08-14 16:16:29
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d467190d8k.htm   iXBRL 8-K 23732
2 EX-99.1 d467190dex991.htm EX-99.1 33343
6 GRAPHIC g467190g0814174756026.jpg GRAPHIC 3517
  Complete submission text file 0001193125-23-212358.txt   187226

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20230814.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20230814_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20230814_pre.xml EX-101.PRE 10805
8 EXTRACTED XBRL INSTANCE DOCUMENT d467190d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 231170447
SIC: 2834 Pharmaceutical Preparations